{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:48:13Z","timestamp":1793119693152,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jad.2024.09.068","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T12:25:00Z","timestamp":1726057500000},"page":"90-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Beta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"368","author":[{"given":"Charlotte","family":"Archer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Wiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2024.09.068_bb0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5\u00ae)","author":"American Psychiatric Association","year":"2013"},{"issue":"12","key":"10.1016\/j.jad.2024.09.068_bb0010","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/0004867418799453","article-title":"Royal Australian and new Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder","volume":"52","author":"Andrews","year":"2018","journal-title":"Australian & New Zealand Journal of Psychiatry"},{"key":"10.1016\/j.jad.2024.09.068_bb0015","unstructured":"Anxiety & Depression Association of America. (2015). Clinical Practice Review for GAD. Retrieved from https:\/\/adaa.org\/resources-professionals\/practice-guidelines-gad."},{"key":"10.1016\/j.jad.2024.09.068_bb0020","unstructured":"Archer, C. (2020). The management of anxiety disorders in UK primary care: a multi-method study. Retrieved from https:\/\/research-information.bris.ac.uk\/ws\/portalfiles\/portal\/266532949\/Final_Copy_2021_01_21_Archer_C_S_PhD_Redacted.pdf."},{"issue":"720","key":"10.1016\/j.jad.2024.09.068_bb0025","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.3399\/BJGP.2021.0561","article-title":"The rise in prescribing for anxiety in UK primary care between 2003 and 2018: a population-based cohort study using CPRD","volume":"72","author":"Archer","year":"2022","journal-title":"Br. J. Gen. Pract."},{"key":"10.1016\/j.jad.2024.09.068_bb0030","doi-asserted-by":"crossref","DOI":"10.3399\/BJGP.2024.0091","article-title":"Exploring GPs\u2019 views on beta-blocker prescribing for people with anxiety disorders: a qualitative study","author":"Archer","year":"2024","journal-title":"British Journal of General Practice."},{"issue":"11\u221212","key":"10.1016\/j.jad.2024.09.068_bb0035","doi-asserted-by":"crossref","first-page":"e1954","DOI":"10.1093\/milmed\/usaa170","article-title":"A preliminary investigation on the effects of atenolol for treating symptoms of anxiety","volume":"185","author":"Armstrong","year":"2020","journal-title":"Mil. Med."},{"key":"10.1016\/j.jad.2024.09.068_bb0040","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2147\/NDT.S36453","article-title":"Pregabalin for the treatment of generalized anxiety disorder: an update","volume":"9","author":"Baldwin","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"27\u201328","key":"10.1016\/j.jad.2024.09.068_bb0045","first-page":"473","article-title":"The diagnosis of and treatment recommendations for anxiety disorders","volume":"111","author":"Bandelow","year":"2014","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.jad.2024.09.068_bb0050","unstructured":"Healthcare Safety Investigation Branch. (2020). Potential under-recognised risk of harm from the use of propranolol. Retrieved from https:\/\/www.hssib.org.uk\/patient-safety-investigations\/potential-under-recognised-risk-of-harm-from-the-use-of-propranolol\/investigation-report\/."},{"issue":"3","key":"10.1016\/j.jad.2024.09.068_bb0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2478\/cpp-2018-0017","article-title":"The role of beta-adrenolytic drugs in treating anxiety disorders","volume":"19","author":"Brudkowska","year":"2018","journal-title":"Current Problems of Psychiatry"},{"key":"10.1016\/j.jad.2024.09.068_bb0060","series-title":"Cochrane Handbook for systematic reviews of interventions","article-title":"Chapter 10: Analysing data and undertaking meta-analyses","author":"Deeks","year":"2022"},{"key":"10.1016\/j.jad.2024.09.068_bb0065","doi-asserted-by":"crossref","first-page":"89","DOI":"10.25149\/1756-8358.1102013","article-title":"Treating anxiety with either beta blockers or antiemetic antimuscarinic drugs: a review","volume":"11","author":"Dooley","year":"2015","journal-title":"Ment Health Fam Med"},{"issue":"1","key":"10.1016\/j.jad.2024.09.068_bb0070","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archpsyc.1972.01750190059011","article-title":"Diagnostic criteria for use in psychiatric research","volume":"26","author":"Feighner","year":"1972","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2024.09.068_bb0075","article-title":"Pharmacotherapy of anxiety disorders: current and emerging treatment options","volume":"1412","author":"Garakani","year":"2020","journal-title":"Front. Psych."},{"issue":"1","key":"10.1016\/j.jad.2024.09.068_bb0080","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"issue":"6","key":"10.1016\/j.jad.2024.09.068_bb0085","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0828-282X(08)70627-5","article-title":"Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006","volume":"24","author":"Hemmelgarn","year":"2008","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.jad.2024.09.068_bb0090","unstructured":"Higgins, J., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M., & Welch, V. e. (2023). Cochrane Handbook for Systematic Reviews of Interventions."},{"issue":"5","key":"10.1016\/j.jad.2024.09.068_bb0095","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00004714-200010000-00011","article-title":"Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial","volume":"20","author":"Hirschmann","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.jad.2024.09.068_bb0100","article-title":"Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines","volume":"13","author":"Huh","year":"2011","journal-title":"The Primary Care Companion to CNS Disorders"},{"issue":"17","key":"10.1016\/j.jad.2024.09.068_bb0105","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2015.13766","article-title":"Trends in prescription drug use among adults in the United States from 1999-2012","volume":"314","author":"Kantor","year":"2015","journal-title":"Jama"},{"issue":"12","key":"10.1016\/j.jad.2024.09.068_bb0110","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1001\/archpsyc.1980.01780250047005","article-title":"Propranolol in chronic anxiety disorders: a controlled study","volume":"37","author":"Kathol","year":"1980","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2024.09.068_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2024.09.068_bb0120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00004850-198707000-00002","article-title":"A double-blind placebo controlled trial of a selective beta 2 adrenoceptor antagonist (ICI 118551) in chronic anxiety","volume":"2","author":"King","year":"1987","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.09.068_bb0130","doi-asserted-by":"crossref","unstructured":"Li, J. (2023). Role of 5-HT receptors and transporters in psychiatric disorders. Paper presented at the second international conference on biological engineering and medical science (ICBioMed 2022).","DOI":"10.1117\/12.2668997"},{"issue":"7","key":"10.1016\/j.jad.2024.09.068_bb0135","first-page":"252","article-title":"Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol","volume":"49","author":"Liebowitz","year":"1988","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2024.09.068_bb0140","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/archpsyc.49.4.290","article-title":"Phenelzine vs atenolol in social phobia: a placebo-controlled comparison","volume":"49","author":"Liebowitz","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"10","key":"10.1016\/j.jad.2024.09.068_bb0145","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.clinthera.2006.10.015","article-title":"Trends in off-label \u03b2-blocker use: a secondary data analysis","volume":"28","author":"Lin","year":"2006","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jad.2024.09.068_bb0150","unstructured":"British Columbia Health Link. (2022). Propranolol - Oral. Retrieved from https:\/\/www.healthlinkbc.ca\/medications\/propranolol-oral#:~:text=Use%20this%20drug%20for%20a,or%20overactive%20thyroid%20(hyperthyroidism)."},{"issue":"9","key":"10.1016\/j.jad.2024.09.068_bb0155","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/PSY.0000000000001009","article-title":"Beta-adrenergic contributions to emotion and physiology during an acute psychosocial stressor","volume":"83","author":"MacCormack","year":"2021","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.jad.2024.09.068_bb0160","first-page":"355","article-title":"Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial","volume":"48","author":"Meibach","year":"1987","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2024.09.068_bb0170","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0010-440X(85)90052-5","article-title":"Imipramine versus propranolol for the treatment of panic attacks: a pilot study","volume":"26","author":"Munjack","year":"1985","journal-title":"Compr. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2024.09.068_bb0175","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00004714-198902000-00005","article-title":"Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks","volume":"9","author":"Munjack","year":"1989","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.09.068_bb0180","unstructured":"NICE. (2011). Generalised anxiety disorder and panic disorder in adults: management Clinical guideline [CG113]. Retrieved from https:\/\/www.nice.org.uk\/guidance\/cg113."},{"issue":"2","key":"10.1016\/j.jad.2024.09.068_bb0185","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0033-3182(82)73433-4","article-title":"Beta-blocking drugs and anxiety","volume":"23","author":"Noyes","year":"1982","journal-title":"Psychosomatics"},{"issue":"3","key":"10.1016\/j.jad.2024.09.068_bb0190","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/archpsyc.1984.01790140077009","article-title":"Diazepam and propranolol in panic disorder and agoraphobia","volume":"41","author":"Noyes","year":"1984","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2024.09.068_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.jad.2024.09.068_bb0200","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.jad.2024.09.068_bb0205","series-title":"Anxiety Disorders in the DSM-5: Changes, Controversies, and Future Directions","first-page":"187","author":"Park","year":"2020"},{"key":"10.1016\/j.jad.2024.09.068_bb0210","first-page":"3","article-title":"Playing with performance: the use and abuse of beta-blockers in the performing arts","volume":"1","author":"Patston","year":"2014","journal-title":"Victorian Journal of Music Education"},{"issue":"3","key":"10.1016\/j.jad.2024.09.068_bb0215","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14740338.2018.1429403","article-title":"Risks and benefits of medications for panic disorder: a comparison of SSRIs and benzodiazepines","volume":"17","author":"Quagliato","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.jad.2024.09.068_bb0220","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00004714-199112000-00003","article-title":"A controlled study of alprazolam and propranolol in: panic-disordered and agoraphobic outpatients","volume":"11","author":"Ravaris","year":"1991","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.jad.2024.09.068_bb0225","first-page":"180","article-title":"Propranolol treatment of generalized anxiety disorder in patients of outpatient psychiatric unit medical specialties","volume":"70","author":"R\u00edos-Morales","year":"2017","journal-title":"Rev. Sanid. Milit."},{"key":"10.1016\/j.jad.2024.09.068_bb0230","doi-asserted-by":"crossref","unstructured":"Rouette, J., McDonald, E. G., Schuster, T., Brophy, J. M., & Azoulay, L. (2022). Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study. BMJ open, 12(6), e057510.","DOI":"10.1136\/bmjopen-2021-057510"},{"key":"10.1016\/j.jad.2024.09.068_bb0235","article-title":"Propranolol hydrochloride","volume":"87","author":"Royal Pharmaceutical Society of Great Britain","year":"2024","journal-title":"British national formulary"},{"key":"10.1016\/j.jad.2024.09.068_bb0240","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/9781119536604.ch14","article-title":"Completing \u2018summary of findings\u2019 tables and grading the certainty of the evidence","author":"Sch\u00fcnemann","year":"2019","journal-title":"Cochrane Handbook for systematic reviews of interventions"},{"issue":"6","key":"10.1016\/j.jad.2024.09.068_bb0245","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archpsyc.1978.01770300115013","article-title":"Research diagnostic criteria: rationale and reliability","volume":"35","author":"Spitzer","year":"1978","journal-title":"Arch. Gen. Psychiatry"},{"issue":"10","key":"10.1016\/j.jad.2024.09.068_bb0250","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch. Intern. Med."},{"issue":"2","key":"10.1016\/j.jad.2024.09.068_bb0255","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0269881115612236","article-title":"Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis","volume":"30","author":"Steenen","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.jad.2024.09.068_bb0260","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1176\/appi.ajp.158.10.1725","article-title":"Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study","volume":"158","author":"Stein","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.09.068_bb0265","doi-asserted-by":"crossref","unstructured":"Sterne, J. A., Savovi\u0107, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., . . . Eldridge, S. M. (2019). RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ open, 366.","DOI":"10.1136\/bmj.l4898"},{"issue":"1","key":"10.1016\/j.jad.2024.09.068_bb0270","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/10401239809148813","article-title":"Betaxolol in anxiety disorders","volume":"10","author":"Swartz","year":"1998","journal-title":"Ann. Clin. Psychiatry"},{"issue":"17","key":"10.1016\/j.jad.2024.09.068_bb0275","doi-asserted-by":"crossref","first-page":"10099","DOI":"10.3390\/ijms231710099","article-title":"Propranolol versus other selected drugs in the treatment of various types of anxiety or stress, with particular reference to stage fright and post-traumatic stress disorder","volume":"23","author":"Szeleszczuk","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jad.2024.09.068_bb0280","series-title":"Anxiety and the Anxiety Disorders","author":"Tuma","year":"2019"},{"issue":"2","key":"10.1016\/j.jad.2024.09.068_bb0285","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1037\/0022-006X.62.2.350","article-title":"Social phobia: a comparison of behavior therapy and atenolol","volume":"62","author":"Turner","year":"1994","journal-title":"Journal of consulting clinical psychology"},{"key":"10.1016\/j.jad.2024.09.068_bb0290","series-title":"The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","volume":"vol. 1","author":"World Health Organisation","year":"1992"},{"key":"10.1016\/j.jad.2024.09.068_bb0295","unstructured":"World Health Organisation. (2023). Anxiety disorders. Retrieved from https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/anxiety-disorders#:\u223c:text=In%20addition%2C%20learning%20stress%20management,treating%20adults%20with%20anxiety%20disorders."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724015532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724015532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:07:55Z","timestamp":1730869675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724015532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":57,"alternative-id":["S0165032724015532"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.09.068","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.09.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}